Ming Lee
@drmjlee.bsky.social
Cat dad. Sexual Health and HIV doctor. He/Him 🏳️🌈
LS-bNAbs were detectable in the gut up to 6m after a single dose, but tissue bNAbs exposurewere 7-8x lower compared to blood.
This long term viral control does not appear to be due to tissue persistence of LS-bNAbs.
This long term viral control does not appear to be due to tissue persistence of LS-bNAbs.
April 10, 2025 at 7:23 AM
LS-bNAbs were detectable in the gut up to 6m after a single dose, but tissue bNAbs exposurewere 7-8x lower compared to blood.
This long term viral control does not appear to be due to tissue persistence of LS-bNAbs.
This long term viral control does not appear to be due to tissue persistence of LS-bNAbs.
Of these group, some experienced rebound while bNAbs were still high, some when the bNAbs were below the 10ug/ml threshold (previously thought to be when bNAbs are no longer effective), and some people who remained fully suppressed despite no bNAbs on board.
April 10, 2025 at 7:23 AM
Of these group, some experienced rebound while bNAbs were still high, some when the bNAbs were below the 10ug/ml threshold (previously thought to be when bNAbs are no longer effective), and some people who remained fully suppressed despite no bNAbs on board.
At the Keystone HIV cure symposium in Durban, South Africa. Looking forward to a great line up of talks and the chance to meet other cure researchers around the globe!
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
April 8, 2025 at 7:01 AM
At the Keystone HIV cure symposium in Durban, South Africa. Looking forward to a great line up of talks and the chance to meet other cure researchers around the globe!
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
Prof Ndung'u opens the meeting with a keynote talk on combination HIV cure approaches in resource limited settings.
4mthly IV/SC N6LS with mthly CAB maintained viral suppression, but there were a small but significant group of people who experienced viral control failure.
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
March 12, 2025 at 7:58 PM
4mthly IV/SC N6LS with mthly CAB maintained viral suppression, but there were a small but significant group of people who experienced viral control failure.
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Like many other bNAb studies, these findings suggest we may have a while to go for the use of bNAbs as a direct antiviral.
#CROI2025
Tecovirimat did not lead to faster clinical resolution, or reduction of pain, for clade 2 MPOX.
We need new agents to treat MPOX.
#CROI2025
We need new agents to treat MPOX.
#CROI2025
March 12, 2025 at 7:31 PM
Tecovirimat did not lead to faster clinical resolution, or reduction of pain, for clade 2 MPOX.
We need new agents to treat MPOX.
#CROI2025
We need new agents to treat MPOX.
#CROI2025
Frailty was associated with an increased risk of MACE in the REPRIEVE study. However frailty did not seem to impact the effectiveness of pitavastatin on preventing MACE outcomes.
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
March 12, 2025 at 6:11 PM
Frailty was associated with an increased risk of MACE in the REPRIEVE study. However frailty did not seem to impact the effectiveness of pitavastatin on preventing MACE outcomes.
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Caveat limited sample size and events in this relatively young cohort assessed with low-mod CVD risk. #CROI2025
Findings from the last gift cohort. Although total HIV DNA measures were similar in the spinal cord (SC) compared to the brain, there was higher HIV diversity seen in the SC. SC may be an important site of HIV dispersal. #CROI2025
March 12, 2025 at 6:08 PM
Findings from the last gift cohort. Although total HIV DNA measures were similar in the spinal cord (SC) compared to the brain, there was higher HIV diversity seen in the SC. SC may be an important site of HIV dispersal. #CROI2025
Roger Paredes on Long COVID. Lots of evidence now that viral persistence seen up to 2yrs after initial infection is seen in people with long COVID. LC is associated with increased thromboinflammation.
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
March 12, 2025 at 4:14 PM
Roger Paredes on Long COVID. Lots of evidence now that viral persistence seen up to 2yrs after initial infection is seen in people with long COVID. LC is associated with increased thromboinflammation.
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
The way forward - greater pt involvement, adaptive RCTs, and vaccination! #CROI2025
At the Stand up for science protest yesterday. There was anger, there was determination. As researchers, clinicians, and activists, we stand together as a community.
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
March 11, 2025 at 3:10 PM
At the Stand up for science protest yesterday. There was anger, there was determination. As researchers, clinicians, and activists, we stand together as a community.
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
And the crowd chanted:
ACT UP, FIGHT BACK.
#CROI2025
There was a signal for enhanced HIV specific immune responses (see posters 505 and 506), and early data suggesting decreases in intact proviral measures of the HIV reservoir (poster 513).
March 10, 2025 at 6:48 PM
There was a signal for enhanced HIV specific immune responses (see posters 505 and 506), and early data suggesting decreases in intact proviral measures of the HIV reservoir (poster 513).
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
March 10, 2025 at 6:48 PM
BNAbs we're safe with no serious adverse events associated with study drug or ATI.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
Some participants experienced extremely high viral loads during ATI, but all achieved viral resuppression after restarting ART.
There were three groups of virological responses seen
1. Those who rebounded early before 20 weeks, likely due to bNAb resistance not picked up by screening assays.
2. Those who rebound after 20 weeks.
3. Those who remained suppressed beyond 72 weeks.
1. Those who rebounded early before 20 weeks, likely due to bNAb resistance not picked up by screening assays.
2. Those who rebound after 20 weeks.
3. Those who remained suppressed beyond 72 weeks.
March 10, 2025 at 6:48 PM
There were three groups of virological responses seen
1. Those who rebounded early before 20 weeks, likely due to bNAb resistance not picked up by screening assays.
2. Those who rebound after 20 weeks.
3. Those who remained suppressed beyond 72 weeks.
1. Those who rebounded early before 20 weeks, likely due to bNAb resistance not picked up by screening assays.
2. Those who rebound after 20 weeks.
3. Those who remained suppressed beyond 72 weeks.
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
March 10, 2025 at 6:48 PM
Prof Sarah Fidler presents the long-awaited results of #RIOstudy of dual bNAbs vs placebo in people with early HIV.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
Pts receiving bNAbs were 91% more likely to experience viral suppression up to 20 weeks compared to placebo, and more than a third remained suppressed after two doses beyond 72 wks.
These signals are promising, and provide a foundation to build on and develop better agents to enhance immune responses towards long-term remission, and eventually, a cure for HIV.
March 10, 2025 at 4:10 PM
These signals are promising, and provide a foundation to build on and develop better agents to enhance immune responses towards long-term remission, and eventually, a cure for HIV.
He eloquently demonstrates, through a case of someone with post bNAb control from the eCLEAR study, that this control likely involves enhanced autologous bNAb responses, Th1 CD4 T cells, and poly functional CD8 T cells controlling viral replication.
March 10, 2025 at 4:10 PM
He eloquently demonstrates, through a case of someone with post bNAb control from the eCLEAR study, that this control likely involves enhanced autologous bNAb responses, Th1 CD4 T cells, and poly functional CD8 T cells controlling viral replication.
Prof Adeeba Kamarulzaman shares how she sought allies, including a religious scholar, to successfully implement opoid replacement harm reduction programmes in Malaysia.
However science isn't enough, and she shares the challenges and progress in changing drug policies and laws.
#CROI2025
However science isn't enough, and she shares the challenges and progress in changing drug policies and laws.
#CROI2025
March 10, 2025 at 1:51 AM
Prof Adeeba Kamarulzaman shares how she sought allies, including a religious scholar, to successfully implement opoid replacement harm reduction programmes in Malaysia.
However science isn't enough, and she shares the challenges and progress in changing drug policies and laws.
#CROI2025
However science isn't enough, and she shares the challenges and progress in changing drug policies and laws.
#CROI2025
A powerful talk by Rebecca Denison, founder of WORLD and woman living with HIV.
We can't go back to the days without treatment access.
Silence is death.
And courage is a decision.
The hall erupted in a standing ovation.
#CROI2025
We can't go back to the days without treatment access.
Silence is death.
And courage is a decision.
The hall erupted in a standing ovation.
#CROI2025
March 10, 2025 at 1:36 AM
A powerful talk by Rebecca Denison, founder of WORLD and woman living with HIV.
We can't go back to the days without treatment access.
Silence is death.
And courage is a decision.
The hall erupted in a standing ovation.
#CROI2025
We can't go back to the days without treatment access.
Silence is death.
And courage is a decision.
The hall erupted in a standing ovation.
#CROI2025
CROI chair Prof Havlir reaffirm the commitment of CROI to support scientific gatherings with free exchange of ideas, and condemns the censoring of science.
She also highlights the response to US federal policy changes.
#CROI2025
She also highlights the response to US federal policy changes.
#CROI2025
March 10, 2025 at 12:12 AM
CROI chair Prof Havlir reaffirm the commitment of CROI to support scientific gatherings with free exchange of ideas, and condemns the censoring of science.
She also highlights the response to US federal policy changes.
#CROI2025
She also highlights the response to US federal policy changes.
#CROI2025
Exciting talk on liver steatosis by Dr Khalili - a number of promising treatments for liver steatosis, including GLP1 agonists (yet another thing GLP1 is good for!) #CROI2025
March 9, 2025 at 9:34 PM
Exciting talk on liver steatosis by Dr Khalili - a number of promising treatments for liver steatosis, including GLP1 agonists (yet another thing GLP1 is good for!) #CROI2025
Dr Joseph Eron gives an excellent overview of cure research highlights at #CROI2025. Why a cure is still needed, and likely strategies including bNAbs cure strategies.
March 9, 2025 at 8:35 PM
Dr Joseph Eron gives an excellent overview of cure research highlights at #CROI2025. Why a cure is still needed, and likely strategies including bNAbs cure strategies.
At CROI San Francisco! #CROI2025
Amidst a sombre mood with uncertainties faced by researchers across the field, we come together in solidarity.
But looking forward to lots of exciting updates, including our #RIOstudy results!
Will be posting updates on bluesky and LinkedIn so follow for updates.
Amidst a sombre mood with uncertainties faced by researchers across the field, we come together in solidarity.
But looking forward to lots of exciting updates, including our #RIOstudy results!
Will be posting updates on bluesky and LinkedIn so follow for updates.
March 9, 2025 at 5:48 PM
Meet Sesame and Olive
I also post cat pictures (for more reasons to follow me).
#ragdoll #britishshorthair
I also post cat pictures (for more reasons to follow me).
#ragdoll #britishshorthair
November 12, 2024 at 6:51 PM
Meet Sesame and Olive
I also post cat pictures (for more reasons to follow me).
#ragdoll #britishshorthair
I also post cat pictures (for more reasons to follow me).
#ragdoll #britishshorthair